Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Piramal Healthcare Chairman Ajay Piramal On Meeting The World's Need For High Quality Delivered At Low Cost: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Ajay Piramal, chairman of the $550 million Piramal Healthcare and Piramal Lifesciences, has brought up his company in the last 20 years, working ceaselessly on signing marketing arrangements with multinational companies for the Indian market, strategic buyouts both in India and abroad, carving out contract manufacturing and then establishing a discovery research entity. Known as the takeover tycoon in Indian corporate circles, Piramal has closed important deals with top-notch global companies like Pfizer. From inheriting a fledgling textiles business in the 1980s to putting together a strong pharmaceutical business from scratch, Ajay Piramal sat down with PharmAsia News' India Bureau to share his vision for the company.
Advertisement

Related Content

Is French Firm Ethypharm's Sudden India Exit Part Of Larger Consolidation?
Is French Firm Ethypharm's Sudden India Exit Part Of Larger Consolidation?
Indian Healthcare Industry To Zoom Past $14 Billion In The Next Three Years; Quadruple By 2017 - KPMG Report
Indian Healthcare Industry To Zoom Past $14 Billion In The Next Three Years; Quadruple By 2017 - KPMG Report
Piramal Healthcare Says Reports Of Sell-off To GSK Or Sanofi-Aventis “Totally Unfounded”
Piramal’s Buyout Of Minrad May Dent Strongholds Of Abbott, Baxter
Advertisement
UsernamePublicRestriction

Register

SC074104

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel